Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 242 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Angiogenesis Clear all
Completed No phase listed Observational

Measurement of Pro-angiogenic Markers in Patients With Hepatic Metastases Undergoing SIRT

NCT00994370
View directory record Official record
Conditions
Liver Cancer
Interventions
Not listed
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 20, 2014 · Synced Oct 27, 2026, 4:50 AM EDT
Completed Phase 3 Interventional

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

NCT01204749
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Interventions
AMG 386, AMG 386 Placebo, Paclitaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Female only
Enrollment
919 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
35
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 27, 2026, 4:50 AM EDT
Recruiting No phase listed Observational

The Impact of Renal Transplant on Coronary Microvascular Function Among Patients With Advanced Chronic Kidney Disease

NCT07222683
View directory record Official record
Conditions
Chronic Kidney Disease, Kidney Transplant, Coronary Microvascular Dysfunction (CMD), Inflammation
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 27, 2026, 4:50 AM EDT
Completed Phase 1Phase 2 Interventional

A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma

NCT00304525
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
RAF265
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
10
States / cities
Aurora, Colorado • Augusta, Georgia • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 27, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma

NCT00284141
View directory record Official record
Conditions
Pulmonary Diseases, Neoplasms, Lung
Interventions
Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 27, 2026, 4:50 AM EDT
Completed Phase 1 Interventional

2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors

NCT00030095
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
2-methoxyestradiol
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 27, 2026, 4:50 AM EDT
Not listed Phase 2 Interventional Results available

Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity

NCT00622726
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Bevacizumab, Conventional Laser for ROP
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
4 Weeks to 22 Weeks
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
15
States / cities
Pasadena, California • Denver, Colorado • Peoria, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Oct 27, 2026, 4:50 AM EDT
Completed No phase listed Observational

Anti-Angiogenic Preeclampsia Milieu Impairs Infant Lung and Vascular Development

NCT02639676
View directory record Official record
Conditions
Preeclampsia
Interventions
Diffusion Lung Capacity (DLCO), Vascular Challenge, Video Imaging, Specimen Collections
Other
Lead sponsor
Indiana University
Other
Eligibility
26 Weeks and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 27, 2026, 4:50 AM EDT
Active, not recruiting Phase 2 Interventional

Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC

NCT03527108
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Nivolumab, Ramucirumab
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 27, 2026, 4:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Clinical Utility of Resistance Training for Improving Cardiovascular Disease Risk in Post-Menopausal Women

NCT03752060
View directory record Official record
Conditions
Cardiovascular Risk Factor, Menopause Related Conditions, Neuromuscular Function, Aerobic Capacity, Inflammation
Interventions
Resistance Exercise, Aerobic Exercise
Behavioral
Lead sponsor
Oklahoma State University
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Stillwater, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 27, 2026, 4:50 AM EDT
Completed Phase 1Phase 2 Interventional

Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue Sarcoma

NCT00023725
View directory record Official record
Conditions
Sarcoma
Interventions
semaxanib, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
207
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 163 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 27, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma

NCT01753713
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
dovitinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
Manmeet Ahluwalia, MD
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 27, 2026, 4:50 AM EDT
Completed Phase 1 Interventional

AZD7451 for Recurrent Gliomas

NCT01468324
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
AZD7451
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 27, 2026, 4:50 AM EDT
Terminated Phase 3 Interventional Results available

Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer

NCT00574275
View directory record Official record
Conditions
Pancreatic Neoplasm
Interventions
Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo, Gemcitabine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Oct 27, 2026, 4:50 AM EDT
Completed Phase 1 Interventional

Phase I - Pre-Radical Prostatectomy RTVP-1 Gene Therapy for Prostate Cancer

NCT00403221
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
RTVP-1 Gene
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2012 · Synced Oct 27, 2026, 4:50 AM EDT
Completed Phase 1 Interventional

EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors

NCT01251926
View directory record Official record
Conditions
Neoplasms
Interventions
EZN-2208, Bevacizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 27, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

NCT00917384
View directory record Official record
Conditions
Gastric Cancer, Adenocarcinoma
Interventions
ramucirumab, Placebo, Best Supportive Care (BSC)
Biological · Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
14
States / cities
Bakersfield, California • La Jolla, California • Redlands, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 27, 2026, 4:50 AM EDT
Completed Phase 1 Interventional Results available

Pazopanib and ARQ 197 for Advanced Solid Tumors

NCT01468922
View directory record Official record
Conditions
Solid Tumor
Interventions
Pazopanib, ARQ 197
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 27, 2026, 4:50 AM EDT
Completed Phase 2 Interventional

PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma

NCT00226005
View directory record Official record
Conditions
Neoplasm
Interventions
PTK787/ZK222584
Drug
Lead sponsor
Pancreatic Cancer Research Team
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
7
States / cities
Scottsdale, Arizona • Tucson, Arizona • Beverly Hills, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Oct 27, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies

NCT00856180
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Bevacizumab, Cyclophosphamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 27, 2026, 4:50 AM EDT
Completed Phase 3 Interventional

Local Warming of Surgical Incisions

NCT01026259
View directory record Official record
Conditions
Surgical Wound Infection
Interventions
Warming of surgical incision, Warming dressing without actual warming
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 4, 2009 · Synced Oct 27, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

NCT01668784
View directory record Official record
Conditions
Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Interventions
Nivolumab, Everolimus
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
821 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
39
States / cities
Fayetteville, Arkansas • La Jolla, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 27, 2026, 4:50 AM EDT
Terminated Phase 2 Interventional Results available

Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer

NCT00549328
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
Pazopanib (GW786034)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
13
States / cities
Scottsdale, Arizona • Fort Myers, Florida • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 27, 2026, 4:50 AM EDT
Completed Phase 1Phase 2 Interventional

ALD-301 for Critical Limb Ischemia, Randomized Trial

NCT00392509
View directory record Official record
Conditions
Critical Limb Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease
Interventions
ALDH-br bone marrow cells vs. mononuclear bone marrow cells
Procedure
Lead sponsor
Aldagen
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Birmingham, Alabama • Atlanta, Georgia • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated May 14, 2009 · Synced Oct 27, 2026, 4:50 AM EDT